SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Approval success rates of drug candidates based on target, action, modality, application, and their combinations
13 references·0 citing·23 second hop
Approval success rates of drug candidates based on target, action, modality, application, and their combinations (2021)Approval success rates of drug candidates…Therapies for rare diseases: therapeutic modalities, progress and challenges ahead (2019)Therapies for rare diseases: …Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)Drug discovery effectiveness …Trends in clinical success rates (2016)Trends in clinical success ra…Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Innovation in the pharmaceuti…Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Lessons learned from the fate…Clinical development success rates for investigational drugs (2014)Clinical development success …Clinical Approval Success Rates for Investigational Cancer Drugs (2013)Clinical Approval Success Rat…Diagnosing the decline in pharmaceutical R&D efficiency (2012)Diagnosing the decline in pha…The productivity crisis in pharmaceutical R&D (2011)The productivity crisis in ph…Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)Trends in Risks Associated Wi…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)How to improve R&D productivi…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…Risks in new drug development: Approval success rates for investigational drugs (2001)Risks in new drug development…The price of innovation: new estimates of drug development costs (2003)Rise and fall of modern medicine (1999)Are Ideas Getting Harder to Find? (2020)Generating Theory by Abduction (2021)Cost of innovation in the pharmaceutical industry (1991)Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances (2005)Economics of New Oncology Drug Development (2007)Deconstructing the Drug Development Process: The New Face of Innovation (2010)Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not) (2000)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)A Proof for the Queuing Formula: L = λ W (1961)The Goal: A Process of Ongoing Improvement (1984)Cost-Effectiveness in Health and Medicine (1996)Essential medicines for universal health coverage (2016)The High Cost of Prescription Drugs in the United States (2016)Changing R&D models in research-based pharmaceutical companies (2016)When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis (2016)A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions (2021)A Comprehensive Map of FDA-Approved Pharmaceutical Products (2018)Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018 (2020)Challenges and opportunities of drug repositioning (2013)Killer Acquisitions (2020)Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases (2021)
this work references cited by second hop

References

  • 2004Can the pharmaceutical industry reduce attrition rates?4,167 cited
  • 2010How to improve R&D productivity: the pharmaceutical industry's grand challenge3,562 cited
  • 2016Innovation in the pharmaceutical industry: New estimates of R&D costs3,352 cited
  • 2014Clinical development success rates for investigational drugs2,531 cited
  • 2012Diagnosing the decline in pharmaceutical R&D efficiency1,978 cited
  • 2014Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework1,344 cited
  • 2011The productivity crisis in pharmaceutical R&D918 cited
  • 2010Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs847 cited
  • 2001Risks in new drug development: Approval success rates for investigational drugs450 cited
  • 2019Therapies for rare diseases: therapeutic modalities, progress and challenges ahead356 cited
  • 2016Trends in clinical success rates277 cited
  • 2013Clinical Approval Success Rates for Investigational Cancer Drugs203 cited
  • 2017Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications148 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work